Biodexa Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Biodexa Pharmaceuticals is Stephen Stamp, benoemd in Sep2019, heeft een ambtstermijn van 5.17 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 252.00K, bestaande uit 99.2% salaris en 0.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde € 4.54. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 7.5 jaar.

Belangrijke informatie

Stephen Stamp

Algemeen directeur

UK£252.0k

Totale compensatie

Percentage CEO-salaris	99.2%
Dienstverband CEO	5.2yrs
Eigendom CEO	0.0002%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Stephen Stamp's beloning veranderd ten opzichte van Biodexa Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-UK£7m
Mar 31 2024	n/a	n/a	-UK£7m
Dec 31 2023	UK£252k	UK£250k	-UK£7m
Sep 30 2023	n/a	n/a	-UK£8m
Jun 30 2023	n/a	n/a	-UK£8m
Mar 31 2023	n/a	n/a	-UK£8m
Dec 31 2022	UK£238k	UK£236k	-UK£8m
Sep 30 2022	n/a	n/a	-UK£7m
Jun 30 2022	n/a	n/a	-UK£5m
Mar 31 2022	n/a	n/a	-UK£5m
Dec 31 2021	UK£329k	UK£187k	-UK£5m
Sep 30 2021	n/a	n/a	-UK£7m
Jun 30 2021	n/a	n/a	-UK£8m
Mar 31 2021	n/a	n/a	-UK£15m
Dec 31 2020	UK£193k	UK£175k	-UK£22m
Jun 30 2020	n/a	n/a	-UK£22m
Mar 31 2020	n/a	n/a	-UK£16m
Dec 31 2019	UK£207k	UK£50k	-UK£9m

Compensatie versus markt: De totale vergoeding ($USD 319.77K ) Stephen } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 473.78K ).

Compensatie versus inkomsten: De vergoeding van Stephen is gestegen terwijl het bedrijf verliesgevend is.

CEO

Stephen Stamp (62 yo)

5.2yrs

Tenure

UK£252,003

Compensatie

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Stamp	CEO, CFO	5.2yrs	UK£252.00k	0.00017% € 4.5
Daniel Palmer	Vice President of Technology	3.8yrs	geen gegevens	geen gegevens
Nicola Tuckwell	VP & Head of Clinical Operations	less than a year	geen gegevens	geen gegevens
Steve Ellul	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Fiona Sharp	Group Financial Controller	no data	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van 5MP1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Stamp	CEO, CFO	5.2yrs	UK£252.00k	0.00017% € 4.5
Simon Turton	Senior Independent Non-Executive Director	9.9yrs	UK£31.92k	0.00017% € 4.5
Stephen Parker	Independent Non-Executive Chairman	2.4yrs	UK£82.00k	geen gegevens
Daniel McCurdy	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sijmen de Vries	Independent Non-Executive Director	20.1yrs	UK£31.92k	0.00017% € 4.5
Michael Natan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Francesco Stellaci	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Male	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lorraine O'Driscoll	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Soledad Penades	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jean-Christophe Roux	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Silke Krol	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 5MP1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

Biodexa Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Recent updates

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023)

Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009969 million.

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009968 million.

Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data

Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ At 12 Months in Familial Adenomatous Polyposis (Fap)

Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis

Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: UK£8.00 loss per share (vs UK£620 loss in FY 2022)

New minor risk - Financial data availability

Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

New major risk - Financial position

Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million.

New major risk - Financial position

Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano)

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs)

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015

Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule

Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements

Biodexa Pharmaceuticals Plc announced that it has received $3.320388 million in funding

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Biodexa Pharmaceuticals Plc (NasdaqCM:BDRX) entered into non-binding letter of intent to acquire Varian Biopharmaceuticals Inc. for $3.7 million.

Full year 2022 earnings released: UK£0.077 loss per share (vs UK£1.36 loss in FY 2021)

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd